# Pharmacokinetics of AGO178 in Participants With Liver Impairment

> **NCT01531309** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** AGO178

## Key facts

- **NCT ID:** NCT01531309
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-08
- **Primary completion:** 2011-09-02
- **Final completion:** 2011-09-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01531309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01531309, "Pharmacokinetics of AGO178 in Participants With Liver Impairment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01531309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*